Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrantROBERTSON, J. F. R; HOWELL, A; GORBUNOVA, V. A et al.Breast cancer research and treatment. 2005, Vol 92, Num 2, pp 169-174, issn 0167-6806, 6 p.Article

Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant)BOUKER, Kerrie B; SKAAR, Todd C; FERNANDEZ, David R et al.Cancer research (Baltimore). 2004, Vol 64, Num 11, pp 4030-4039, issn 0008-5472, 10 p.Article

Fulvestrant : Neue Therapieoption beim hormon sensiblen, fortgeschrittenen Mammakarzinom = Fulvestrant : New therapeutic option for hormone sensitive, advanced breast cancerMAASS, N; HILPERT, F; JONAT, W et al.Geburtshilfe und Frauenheilkunde. 2005, Vol 65, Num 4, pp 362-367, issn 0016-5751, 6 p.Article

Endocrine treatment options for advanced breast cancer: the role of fulvestrant. CommentaryROBERTSON, J. F. R; COME, S. E; JONES, S. E et al.European journal of cancer (1990). 2005, Vol 41, Num 3, pp 344-345, issn 0959-8049, 14 p.Article

MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathwaysRAO, X; DI LEVA, G; LI, M et al.Oncogene (Basingstoke). 2011, Vol 30, Num 9, pp 1082-1097, issn 0950-9232, 16 p.Article

Role for HER2/neu and HER3 in fulvestrant-resistant breast cancerOSIPO, Clodia; MEEKE, Kathleen; DONG CHENG et al.International journal of oncology. 2007, Vol 30, Num 2, pp 509-520, issn 1019-6439, 12 p.Article

Fulvestrant ('Faslodex') : Current and future role in breast cancer managementHOWELL, Anthony.Critical reviews in oncology/hematology. 2006, Vol 57, Num 3, pp 265-273, issn 1040-8428, 9 p.Article

Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer : A single-centre experienceSTEGER, G. G; BARTSCH, R; WENZEL, C et al.European journal of cancer (1990). 2005, Vol 41, Num 17, pp 2655-2661, issn 0959-8049, 7 p.Article

Fulvestrant (Faslodex®): extending the reach of endocrine therapy?JOHNSTON, Stephen R.Breast cancer research and treatment. 2005, Vol 93, issn 0167-6806, 26 p., SUP1Serial Issue

Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: A Japanese studyWATANABE, Toru; SANO, Muneaki; OHNO, Shinji et al.Anticancer research. 2004, Vol 24, Num 2C, pp 1275-1280, issn 0250-7005, 6 p.Article

Fulvestrant in postmenopausal women with advanced breast cancerBROSS, Peter F; BAIRD, Amy; WILLIAMS, Grant et al.Clinical cancer research. 2003, Vol 9, Num 12, pp 4309-4317, issn 1078-0432, 9 p.Article

Advances in endocrine therapy of metastatic breast cancerGRADISHAR, W. J; MORROW, M.British journal of surgery. 2002, Vol 89, Num 12, pp 1489-1492, issn 0007-1323, 4 p.Article

Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM TrialDI LEO, Angelo; JERUSALEM, Guy; PENDERGRASS, Kelly et al.Journal of the National Cancer Institute. 2014, Vol 106, Num 1, issn 0027-8874, 337.1-337.7Article

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodologyGARNETT, Sally Anne; MARTIN, Miguel; LICHINITSER, Mikhail R et al.Breast cancer research and treatment. 2013, Vol 138, Num 1, pp 149-155, issn 0167-6806, 7 p.Article

Finding the right dose of fulvestrant in breast cancerESTEVEZ, L; ALVAREZ, I; TUSQUETS, I et al.Cancer treatment reviews. 2013, Vol 39, Num 2, pp 136-141, issn 0305-7372, 6 p.Article

Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complexGIESSRIGL, B; SCHMIDT, W. M; KALIPCIYAN, M et al.British journal of cancer. 2013, Vol 109, Num 10, pp 2751-2762, issn 0007-0920, 12 p.Article

Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapyVERGOTE, I; ROBERTSON, J. F. R; KLEEBERG, U et al.Breast cancer research and treatment. 2003, Vol 79, Num 2, pp 207-211, issn 0167-6806, 5 p.Article

Fulvestrant ^(Faslodex°). Cancer du sein avancé en 2^e ligne : Moins de troubles ostéo-articulaires = Fluvestrant (Faslodex) advanced breast cancer: less osteoarticular disorderLa Revue Prescrire. 2005, Vol 25, Num 260, issn 0247-7750, p. 264Article

Estrogen receptor downregulators: New antihormonal therapy for advanced breast cancerROBERTSON, John F.Clinical therapeutics. 2002, Vol 24, pp A17-A30, issn 0149-2918, SUPAArticle

Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor α to vinblastine and vinorelbineMEIHUA SUI; DONGHAI JIANG; HINSCH, Claire et al.Breast cancer research and treatment. 2010, Vol 121, Num 2, pp 335-345, issn 0167-6806, 11 p.Article

Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer : single centre clinical experience from the compassionate use programmeMLINERITSCH, Brigitte; PSENAK, Oskar; MAYER, Peter et al.Breast cancer research and treatment. 2007, Vol 106, Num 1, pp 105-112, issn 0167-6806, 8 p.Article

A NOVEL CLASS OF POLYMERIC CARRIERS BASED ON PLA-MPEG FOR MICROSPHERE CONTAINING FULVESTRANTJIUCHENG WANG; DAN LIANG; GUOZHENG LIANG et al.Journal of polymer engineering. 2010, Vol 30, Num 2, pp 81-94, issn 0334-6447, 14 p.Article

Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia : results from two randomized, proof-of-concept studiesGASSMUELLER, J; HOFFMANN, R; WEBSTER, A et al.British journal of dermatology (1951). 2008, Vol 158, Num 1, pp 109-115, issn 0007-0963, 7 p.Article

Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancerROBERTSON, John F. R; ODLING-SMEE, William; HOLCOMBE, Chris et al.Clinical therapeutics. 2003, Vol 25, Num 5, pp 1440-1452, issn 0149-2918, 13 p.Article

Electrochemical determination of anticancer drug fulvestrant at dsDNA modified pencil graphite electrodeDOGAN-TOPAL, Burcu; OZKAN, Sibel A.Electrochimica acta. 2011, Vol 56, Num 12, pp 4433-4438, issn 0013-4686, 6 p.Article